Literature DB >> 12527911

NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells.

Mohamed Bentires-Alj1, Veronique Barbu, Marianne Fillet, Alain Chariot, Biserka Relic, Nathalie Jacobs, Jacques Gielen, Marie-Paule Merville, Vincent Bours.   

Abstract

The ubiquitous NF-kappaB transcription factor has been reported to inhibit apoptosis and to induce drug resistance in cancer cells. Drug resistance is the major reason for cancer therapy failure and neoplastic cells often develop multiple mechanisms of drug resistance during tumor progression. We observed that NF-kappaB or P-glycoprotein inhibition in the HCT15 colon cancer cells led to increased apoptotic cell death in response to daunomycin treatment. Interestingly, NF-kappaB inhibition through transfection of a plasmid coding for a mutated IkappaB-alpha inhibitor increased daunomycin cell uptake. Indeed, the inhibition of NF-kappaB reduced mdr1 mRNA and P-glycoprotein expression in HCT15 cells. We identified a consensus NF-kappaB binding site in the first intron of the human mdr1 gene and demonstrated that NF-kappaB complexes could bind with this intronic site. Moreover, NF-kappaB transactivates an mdr1 promoter luciferase construct. Our data thus demonstrate a role for NF-kappaB in the regulation of the mdr1 gene expression in cancer cells and in drug resistance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12527911     DOI: 10.1038/sj.onc.1206056

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  113 in total

1.  Cytotoxicity of nimbolide towards multidrug-resistant tumor cells and hypersensitivity via cellular metabolic modulation.

Authors:  Nuha Mahmoud; Mohamed E M Saeed; Yoshikazu Sugimoto; Sabine M Klauck; Henry J Greten; Thomas Efferth
Journal:  Oncotarget       Date:  2018-11-06

2.  Evolution of resistance during clonal expansion.

Authors:  Yoh Iwasa; Martin A Nowak; Franziska Michor
Journal:  Genetics       Date:  2006-04       Impact factor: 4.562

3.  Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation.

Authors:  Su-Fern Tan; Wendy Dunton; Xin Liu; Todd E Fox; Samy A F Morad; Dhimant Desai; Kenichiro Doi; Mark R Conaway; Shantu Amin; David F Claxton; Hong-Gang Wang; Mark Kester; Myles C Cabot; David J Feith; Thomas P Loughran
Journal:  J Lipid Res       Date:  2019-04-08       Impact factor: 5.922

4.  Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine.

Authors:  Chong-Chong Gao; Xiao-Lan Xu; Fei Li; Ben-Gang Gong; Shuang Liu; Ye-Qing Cui; Hai-Chen Sun; Ping-Yong Xu; Ya-Min Zheng; Hua Jiang
Journal:  Tumour Biol       Date:  2015-12-18

Review 5.  Inflammation and stem cells in gastrointestinal carcinogenesis.

Authors:  Michael Quante; Timothy Cragin Wang
Journal:  Physiology (Bethesda)       Date:  2008-12

6.  Transferrin-targeted polymeric micelles co-loaded with curcumin and paclitaxel: efficient killing of paclitaxel-resistant cancer cells.

Authors:  Abraham H Abouzeid; Niravkumar R Patel; Can Sarisozen; Vladimir P Torchilin
Journal:  Pharm Res       Date:  2014-02-13       Impact factor: 4.200

7.  UDP-glucose ceramide glucosyltransferase activates AKT, promoted proliferation, and doxorubicin resistance in breast cancer cells.

Authors:  Marthe-Susanna Wegner; Nina Schömel; Lisa Gruber; Stephanie Beatrice Örtel; Matti Aleksi Kjellberg; Peter Mattjus; Jennifer Kurz; Sandra Trautmann; Bing Peng; Martin Wegner; Manuel Kaulich; Robert Ahrends; Gerd Geisslinger; Sabine Grösch
Journal:  Cell Mol Life Sci       Date:  2018-03-17       Impact factor: 9.261

Review 8.  Mechanisms of drug resistance in colon cancer and its therapeutic strategies.

Authors:  Tao Hu; Zhen Li; Chun-Ying Gao; Chi Hin Cho
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

9.  The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.

Authors:  Robert O'Connor; Melissa G Ooi; Justine Meiller; Jana Jakubikova; Steffen Klippel; Jake Delmore; Paul Richardson; Kenneth Anderson; Martin Clynes; Constantine S Mitsiades; Peter O'Gorman
Journal:  Cancer Chemother Pharmacol       Date:  2013-04-16       Impact factor: 3.333

10.  Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B.

Authors:  Yao Dai; Theodore S Lawrence; Liang Xu
Journal:  Am J Transl Res       Date:  2009-01-01       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.